Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amygdala Acquires Gilead's Addiction Disorder Candidiate | Contract Pharma

What are you searching for?

Sign in
Breaking News

Amygdala Acquires Gilead’s Addiction Disorder Candidiate

Phase II ready asset has potential to become a treatment for addiction

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amygdala Neurosciences Inc., a biopharma company developing drug candidates for addiction disorders, has entered into an agreement with Gilead Sciences to acquire GS-6637, a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions based on a mechanism of action that prevents dopamine surges and associated craving without changes to basal dopamine.  

“Completion of this transaction launches Amygdala Neurosciences with a Phase-2 ready asset that we believe has the potential to become a treatment for addiction,” said Peter Strumph, Amygdala’s co-founder and chief executive officer. “In 2017, we look forward to initiating clinical trials for the treatment of both cocaine and alcohol use disorders.”

“Preventing relapse is a critical treatment objective. When exposed to stimuli associated with drug use, addicts experience a pathophysiologic dopamine surge that leads to craving and promotes drug relapse,” said Ivan Diamond, MD, Ph.D., and Amygdala’s co-founder and CSO. “In animal studies, GS-6637 decreased drug use and relapse by preventing the stimuli induced pathophysiologic dopamine surges which result in craving and drug seeking behavior.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics